drugset
drugset / Trial / NCT03445208

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

NCT03445208 ↗

Phase 1 Completed 30 enrolled Bristol-Myers Squibb
Non-randomizedCrossoverOpen-labelTreatment

Summary

This is a study of experimental medication BMS-986036 given to healthy participants.

Timeline

Start
2018-02-14
Primary completion
2018-05-02
Completion
2018-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegbelfermin Protein / enzyme biologic — —

Indications

NAFLD1 cirrhosis of liver fibrotic liver disease metabolic dysfunction-associated steatohepatitis